SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Le Roith D. Insulin-like growth factors. N Engl J Med 1997; 336: 63340.
  • 2
    Krywicki RF, Yee D. The insulin-like growth factor family of ligands, receptors and binding proteins. Breast Cancer Res Treat 1992; 22: 719.
  • 3
    De Leon DD, Bakker B, Wilson DM, Lamson G, Rosenfeld RG. Insulin -like growth factor binding proteins in human breast cancer cells: relationship to hIGFBP-2 and hIGFBP-3. J Clin Endocrinol Metab 1990; 71: 5302.
  • 4
    Baker J, Liu J-P, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 7382.
  • 5
    Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effect of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocrinol Rev 2000; 21: 21544.
  • 6
    Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 12248.
  • 7
    Smith GD, Gunnell D, Holly J. Cancer and insulin-like growth factor I. Br Med J 2000; 321: 8478.
  • 8
    Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997; 145: 9706.
  • 9
    Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrinol Rev 1995; 16: 334.
  • 10
    Werner H, Le Roith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68: 183223.
  • 11
    Kleinberg DL. Role of IGF-I in normal mammary development. Breast Cancer Res Treat 1998; 47: 2018.
  • 12
    Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 1993; 29A: 4927.
  • 13
    Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast. Cancer Res Treat 1998; 47: 20917.
  • 14
    Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast. Cancer Res Treat 1992; 22: 219.
  • 15
    De Leon DD Wilson, DM, Powers M, Rosenfeld RG. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells. Growth Factors 1992; 6: 32736.
  • 16
    Peyrat JP, Bonneterre J. Type 1 IGF receptor in human breast diseases. Breast. Cancer Res Treat 1992; 22: 5967.
  • 17
    Brünner, N, Moser, C, Clarke, R, Cullen, K. IGF-I and IGF-II expression in human breast cancer xenografts: relationship to hormone independence. Breast Cancer Res Treat 1992; 22: 3945.
  • 18
    Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 1986; 46: 46139.
  • 19
    Figueroa JA, Yee D. The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. Breast Cancer Res Treat 1992; 22: 8190.
  • 20
    Gill ZP, Perks CM, Newcomb PV, Holly JM. Insulin-like growth factor-binding protein 3 (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF dependent manner. J Biol Chem 2 1997; 72: 256027.
  • 21
    Karas M, Danilenko M, Fishman D, Le Roith D, Levy J, Sharon Y. Membrane-associated insulin-like growth factor binding protein-3 inhibits insulin-like growth factor-I induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells. J Biol Chem 1997; 272: 1651420.
  • 22
    Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 2000; 92: 19117.
  • 23
    Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 5636.
  • 24
    Lacey JV Jr, Hsing AW, Fillmore C-M, Hoffman S, Helzsouer K, Comstock GW. Null association between insulin-like growth factors, insulin-like growth factor-binding proteins, and prostate cancer in a prospective study. Cancer Epidemiol Biomark Prev 2001; 10: 11012.
  • 25
    Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor (IGF-I), IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 425865
  • 26
    Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 15921606.
  • 27
    Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomark Prev 2000; 9: 3459.
  • 28
    Palmqvist R, Hallmans G, Rinakdi S, Biessy C, Stenling R, Riboli E, Kaaks R. Plasma insulin-like growth factor I, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in Northern Sweden. Gut 2002; 50: 6426.
  • 29
    Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-bonding protein-3. J. Natl Cancer Inst 1999; 91: 6205.
  • 30
    Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001; 85: 16959.
  • 31
    Lukanova A, Toniolo P, Akhmedkhanov A, Biessy C, Naley NJ, Shore RE, Riboli E, Rinaldi S, Kaaks R. A prospective study of insulin-like growth factor-I, IGF-binding protiens-1, -2 and –3 and lung cancer risk in women. Int J Cancer 2001; 92: 88892.
  • 32
    London SJ, Yuan JM, Travlos GS, Gao YT, Wilson RE, Ross RK, Yu MC. Insulin-like growth factor I, IGF-binding protein 3 and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002; 94: 74954.
  • 33
    Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiol Biomarkers Prev 2002; 11: 14138.
  • 34
    Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud D, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 13936.
  • 35
    Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrér JMG, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000; 88: 82832.
  • 36
    Kaaks R, Lundin E, Manjer J, Rinaldi S, Biessy C, Söderberg S, Lenner P, Janzon L, Riboli E, Berglund G, Hallmans G. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Caus Control 2002; 13: 30716.
  • 37
    Keinan Boker L, van Noord PAH, van der Schouw YT Koot, VCM, Bueno de Mesquita HB, Riboli E, Grobbee DE, Peeters PHM. Prospect-EPIC Utrecht: Study design and characteristics of the cohort population. Eur J Epidemiol 2001; 17: 104753.
  • 38
    Verschuren WMM, van Leer EM, Blokstra A, Seidell JC, Smit HA, Bueno de Mesquita HB, Oberman-de Boer GL, Kromhout D. Cardiovascular disease risk factors in The Netherlands. Neth J Cardiol 1993; 6: 20510.
  • 39
    SPSS Inc. Statistical Package version 9.0. Chicago. 1998.
  • 40
    Egret for windows. Cytel statistical software corporation, Cambridge MA, USA.
  • 41
    Smith JC, Lewis S, Holbrook J, Seidell K, Rose, A. Effect of heparine and citrate on measured concentrations of various analytes in plasma. Clin Chem 3 1987; 3: 8146.
  • 42
    Groschl M, Wanger R, Dorr HG, Blum W, Rascher W, Dotsch J. Variability of leptin values measured from different sample matrices. Horm Res 2000; 54: 2631.
  • 43
    Yang G, Lu G, Jin F, Dai Q, Best R, Shu X-O, Chen J-R, Pan X-Y, Shrubsole M, Zheng W. population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 120711.
  • 44
    Bruning PF, van Doorn J, Bonfrér JMG, van Noord PAH, Korse CM, Linders TC, Hart AAM. Insulin-like growth factor binding protein-3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 1995; 62: 26670.
  • 45
    Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PL. Insulin and related factors in premenopausal breast cancer risk. Breast. Cancer Res Treat 1998; 47: 11120.
  • 46
    Sachdev D, Yee D. The IGF system and breast cancer. Endocrin Related Cancer 2001; 8: 197209.
  • 47
    Kaaks R, Lukanova A. Nutrition, hormones and breast cancer: is insulin the missing link? Cancer Caus Control 1996; 7: 56971.
  • 48
    Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor I. Proc Nutr Soc 2001; 60: 91106.
  • 49
    Ruan W, Catanese V, Wieczorek R, Feldman M, Kleinberg DL. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone induced IGF-I messenger ribonucleic acid. Endocrinology 1995; 36: 1296302.